Allogeneic islet products for type 1 diabetes: Navigating nonclinical and manufacturing regulatory expectations
Chengyuan Press, Kevin Damour, Nicholas Mamrak, David Pepperl et autres
0 citationsStem Cell Reports
Marjana Marinac
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
18Publications signalées
445Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Diabetes Management and ResearchDiabetes and associated disordersPancreatic function and diabetesDiabetes Management and EducationDiabetes Treatment and Management
Publications récentes
Adults with type 1 diabetes define what matters to them in stem-cell derived islet cell therapy
Jane Speight, Sufyan Hussain, Ananthi Anandhakrishnan, Thomas Danne et autres
1 citationNature Medicine
Perceptions of the Benefits and Risks of Novel Therapies for Type 1 Diabetes: A Qualitative Study
Stephen R. Karpen, Richard Mellor, Linda A. DiMeglio, Peter Senior et autres
0 citationsDiabetes Therapy
Future Directions and Clinical Trial Considerations for Novel Islet β-Cell Replacement Therapies for Type 1 Diabetes
Marjana Marinac, Michael R. Rickels, Jason L. Gaglia, Philip J. O’Connell et autres
5 citationsDiabetes
TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial
Cassandra Bazile, Magdy M Abdel Malik, Courtney Ackeifi, Randy L. Anderson et autres
21 citationsFrontiers in Immunology
Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead
Alessandro Grattoni, Gregory S. Korbutt, Alice A. Tomei, Andrés J. Garcı́a et autres
86 citationsNature Reviews Endocrinology
Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes
Esther Latres, Carla J. Greenbaum, Maria L. Oyaski, Colin Dayan et autres
33 citationsDiabetes
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
Peter Taylor, Kimberly S. Collins, Anna Lam, Stephen R. Karpen et autres
60 citationsThe Lancet Diabetes & Endocrinology
182-OR: C-Peptide and Metabolic Outcomes in Immunotherapy Studies of New-Onset Type 1 Diabetes
Peter W. Taylor, Kimberly S. Collins, Stephen R. Karpen, Elnaz Atabakhsh et autres
0 citationsDiabetes
Erratum. Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes. Diabetes Care 2022;45:2189–2201
Randy L. Anderson, Linda A. DiMeglio, Adrian Mander, Colin Dayan et autres
1 citationDiabetes Care
Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes
Randy L. Anderson, Linda A. DiMeglio, Adrian Mander, Colin Dayan et autres
23 citationsDiabetes Care
Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies
Stephen R. Karpen, Jessica L. Dunne, Brigitte I. Frohnert, Marjana Marinac et autres
11 citationsDiabetologia
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.